Valion Bio Seeks Approval for 1-for-2 to 1-for-12 Reverse Split and 272K Share Plan Increase
VBIO sits 17% above its 52-week low of $2.05 on light trading volume (0.1× avg).
Summary
Valion Bio filed a preliminary proxy seeking shareholder approval for a reverse stock split (1-for-2 to 1-for-12) and a 272,000-share increase to its equity incentive plan. The reverse split aims to maintain Nasdaq listing compliance; the plan increase triples the share reserve for employee compensation.
Key Events · Corporate Governance and Compliance · VBIO
-
Reverse Split Ratio Narrowed to 1-for-2 to 1-for-12
Board seeks discretionary authority to effect a reverse split within 12 months of approval, down from the 1-for-5 to 1-for-50 range proposed in July 2026. At 1-for-12, outstanding shares would drop from 1,285,731 to 107,145.
-
Equity Plan Reserve Increased by 272,000 Shares
Proposal 2 would raise the 2021 Equity Incentive Plan share reserve from 128,783 to 400,783 shares, a 211% increase. Only 114,121 shares remain available for future grants as of September 15, 2026.
-
Nasdaq Listing Compliance at Stake
The reverse split is primarily aimed at maintaining the $1.00 minimum bid price required for Nasdaq Capital Market listing. The stock closed at $2.11 on September 15, 2026, but the board cites volatility and recent low prices as justification for the authorization.
-
Pro-Forma Dilution of 4.94% from Plan Amendment
The company projects 5,500,764 pro-forma partially-diluted shares outstanding after the plan increase, with the 400,783-share plan reserve representing 4.94% overhang. This assumes full conversion of Series A, B, and C preferred stock.
Analysis · VBIO · Life Sciences
Valion Bio is asking shareholders to approve a reverse stock split at a ratio between 1-for-2 and 1-for-12, a significant narrowing from the 1-for-5 to 1-for-50 range proposed in July 2026. The company also wants to add 272,000 shares to its equity incentive plan, more than tripling the current reserve. With the stock at $2.40 and Nasdaq's $1.00 minimum bid rule looming, the reverse split is a defensive move to maintain listing compliance. The equity plan increase signals the board expects to use stock-based compensation heavily to retain talent while cash remains tight — the company reported only $2.1M in cash as of August 2026 and reiterated going concern doubt.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $2.05 to $78.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.